Semliki Forest virus (SFV) vectors are promising tools for cancer gene therapy because they ensure a high level of transgene expression and a rapid and strong cytopathic effect. However, broad tissue tropism and transient expression make it more difficult to develop an optimal cancer treatment strategy. In this study, we have compared the distribution of recombinant SFV particles (recSFV) and naked viral RNA replicon (recRNA) in tumor-free and 4T1 mammary tumor-bearing mice as a consequence of different vector administration strategies. The high potential of SFV recRNA as a biosafe approach for the development of therapeutic treatment was demonstrated. Intravenous (i.v.) inoculation of recRNA provided primary brain targeting in both tumor-free and 4T1 tumor mouse models, but local intratumoral inoculation revealed a high expression level in tumors. Moreover, we observed the predominant tumor targeting of recSFV at a reduced viral dose on i.v. and intraperitoneal (i.p.) virus inoculation, whereas the dose increase led to a broad virus distribution in mice. To prolong transgene expression, we have tested several i.v. and i.p. reinoculation strategies. A detailed evaluation of vector distribution and readministration properties could have an impact on cancer gene therapy clinical trial safety and efficacy.
INTRODUCTION
The latest virus-based technologies have significantly contributed to the progress of cancer therapy. 1, 2 Among other recombinant viruses, alphaviral vectors are efficient mammalian expression systems, allowing transient high-level transgene expression and rapid high-titer recombinant particle production. 3, 4 These vectors are promising in the field of cancer gene therapy because of their strong cytopathic effects through the induction of p53-independent apoptosis, 5, 6 their ability to efficiently overcome immunological tolerance by the activation of innate antiviral pathways 7, 8 and the subsequent triggering of the cytotoxic T-lymphocyte response against tumors. 9, 10 The advantages also include a low specific immune response against the vector itself, the absence of vector pre-immunity and a high level of biosafety. 11, 12 Alphaviruses are enveloped viruses containing a positive-strand RNA genome and belonging to the Togaviridae family. 13 The classical Semliki Forest virus (SFV) replicon vector is generated in such a way that the heterologous insert replaces the structural genes under the control of the 26S viral subgenomic promoter. 14 The vector RNA can be packaged into recombinant viral particles by co-transfection into cells together with a helper RNA that encodes structural genes (capsid and envelope). On infection, the SFV RNA can replicate and lead to high expression of the heterologous gene; however, the vector cannot propagate because it lacks genes coding for viral structural proteins.
SFV can efficiently infect and induce apoptosis in many types of cancer cells in vitro. 15, 16 However, in contrast to the closely related Sindbis virus, specific tumor targeting by SFV vectors has not been confirmed in vivo. 17 Therefore, the most commonly used approach has been intratumoral (i.t.) injection of SFV vectors carrying a reporter and/or a therapeutic gene. Therapeutic efficacy by direct, repeated i.t. injections of recombinant SFV (recSFV) has been shown in several mouse tumor models, demonstrating tumor growth inhibition or complete regression. 18--22 Despite the promising treatment results, local i.t. vector administration has some disadvantages. For example, many tumors are not readily accessible for i.t. administration. Furthermore, this inoculation type is not appropriate for metastasis treatment, and i.t. injection doses are limited. Systemic administration may be the most effective method to reach various metastatic sites and is much more amenable than a surgical procedure from a translational perspective. However, the systemic application of oncolytic vectors is limited by their toxicity; therefore, the virus distribution has to be carefully investigated in tumor-free and tumor-bearing animal models.
A broad SFV dissemination by systemic administration has been shown in mouse models. 17, 23 The intravenous (i.v.) and intraperitoneal (i.p.) injection of recSFV particles resulted in a similar recombinant virus distribution with high infectivity detected in the heart and lung and moderate infectivity detected in other organs. To prolong the transgene expression that significantly drops on just the third day after inoculation, systemic vector reinjection attempts within a 20-day interval were performed. 17 These reinjection results showed that the vector expression was only slightly above background in all of the organs tested, indicating recombinant virus activity inhibition by the immune system. Nevertheless, the vector injection method (i.v., i.p. and i.t.), dose, and reinjection strategy may significantly contribute to the virus targeting and transgene expression efficacy, which has not been evaluated in detail thus far.
Taking into consideration that the SFV replicon vector is based on in vitro transcribed RNA, the corresponding RNA (recRNA) (naked or encapsulated into transfection vesicles) can be used as an alternative vector for cancer therapy. Self-replicating RNA can provide the same efficient cytoplasmic transgene expression and induction of apoptosis in the host cells, and it is safe for in vivo application and does not induce antivector immunity. 24--26 The high potential of recSFV RNA as a tumor vaccine was shown in one study where intramuscular injection of as little as 1 mg of naked SFV RNA provided complete tumor protection and extended the survival of treated mice when tumor cells were injected 2 days before immunization. 27 To develop optimal treatment strategies regarding the viral dose, the administration method and the regimen, we performed a detailed study of SFV biodistribution in tumor-free, immunocompetent Balb/c mice and 4T1 mammary tumor-bearing mice. 4T1 is a mouse transplantable tumor cell line that is highly tumorigenic and invasive. 28 In contrast to previous studies, we have demonstrated that reduced dosage of recSFV provides preferential SFV infection in 4T1 tumor nodules, whereas the dosage increase contributes to broad dissemination of infection in the organism. Moreover, for the first time, the biodistribution of naked SFV recRNA in tumor-free and tumor-bearing mice was investigated on i.v., i.p. and i.t. RNA administration. Finally, we have tested several readministration strategies using recSFV particles and recRNA. This study emphasizes the importance of the vector inoculation method and highlights the relevance of systemic SFV injection (viral particles and naked RNA) in the context of transgene distribution and tumor delivery.
MATERIALS AND METHODS

Cell lines and animals
The BHK-21 cells (baby hamster kidney cells) and the tumor cell line 4T1 (metastasizing mammary carcinoma from BALB/c mouse) were obtained from the American Type Culture Collection (ATCC/LGC Prochem, Boras, Sweden). BHK-21 cells were propagated in BHK---Glasgow MEM (GIBCO/ Invitrogen, Paisley, UK) supplemented with 5% fetal bovine serum (FBS), 10% tryptose phosphate broth, 2 mM L-glutamine, 20 mM HEPES and antibiotics (streptomycin 100 mg ml --1 and penicillin 100 U ml --1 ). The 4T1 cell line was cultured in Dulbecco's minimal essential medium (GIBCO/ Invitrogen) supplemented with 10% FBS, 2 mM L-glutamine and antibiotics.
Specific pathogen-free 4-to 6-week-old female BALB/c mice were obtained from Latvian Experimental Animal Laboratory of Riga Stradins University and maintained under pathogen-free conditions in accordance with the principles of the Latvian and European Community laws. All experiments were approved by the local Animal Protection Ethical Committee and the Latvian Food and Veterinary Service (permission for animal experiments no. 32/23.12.2010).
Construction of the pSFV1/Enh.Luc expression vector
The pSFV1/Enh vector was generated based on the pSFV1 vector 14 by insertion of the 5 0 region of SFV capsid gene sequence (36 codons), acting as a translational enhancer for efficient heterologous gene expression, under the control of the 26S subgenomic promoter. This element is followed by in-frame insertion of foot-and-mouth-disease virus 2A autoprotease sequence. 29 Located downstream of this cassette, the polylinker allows for the cloning of a gene of interest. The firefly luciferase gene (Luc) was amplified by PCR using the pGL3-Basic (Promega, Madison, WI, USA) plasmid as a template. The primers for amplification were as follows: 5 0 -GACCCGGGAAGGATCTCTCGAGGATGGAAGAC-3 0 (forward) and 5 0 -CCGTTTAAACTATCCTAGAATTACACGGCGATCTTTCCGCCCTTC-3 0 (reverse). The Luc PCR fragment was cut using SmaI and PmeI restriction enzymes and ligated into the pSFV1/Enh vector, which had also been cleaved with the same enzymes. The resulting pSFV1/Enh.Luc vector carries the Luc gene fused with the SFV core enhancer and 2A autoprotease-encoding sequence at the 5 0 end. The presence of the SFV enhancer provides an approximate 10-fold increase in the transgene expression in comparison with the classical SFV1 vector. 18 The foreign Nterminal 36 aa, which may affect the luciferase enzymatic activity, are removed by the activity of 2A autoprotease.
In vitro RNA transcription and recSFV virus production
The synthesis of recSFV RNA and the generation of infectious vector particles have been previously described. 30 Briefly, pSFV1/Enh.Luc and pSFV-helper 14 plasmids were linearized using the SpeI restriction enzyme (Fermentas, Vilnius, Lithuania). In vitro RNA transcription was performed using 3 mg of linearized DNA and 40 U of SP6 RNA polymerase (Fermentas) in a 50 ml reaction mixture. The RNA transcripts were capped during the transcription reaction by adding 1 mM of the 5 0 (ppp)5 0 G cap-analogue (New England Biolabs, Hitchin, UK). The DNA template was removed by digestion using RNase-free DNase (Fermentas).
For the packaging of pSFV1/Enh.Luc RNA (recRNA) into SFV particles (recSFV), in vitro transcribed RNAs (recRNA and SFV-helper RNA, 20 mg each) were co-electroporated into 1 Â 10 7 BHK cells (850 V, 25 mF, 2 pulses) using a Bio-Rad Gene Pulser apparatus (Bio-Rad, Hercules, CA, USA) without the pulse controller unit. The electroporated cells were resuspended in 15 ml of complete BHK medium containing 1% FBS, transferred into tissue culture flasks (75 cm 2 ) and incubated at 37 1C (5% CO 2 ). After a 24-h incubation, recSFV-containing medium was harvested, rapidly frozen and subsequently used as a virus stock. The virus stocks did not contain the replication proficient wild-type virus (confirmed by cell reinfection).
To concentrate recSFV particles, 25 ml of the virus-containing medium was ultracentrifuged through a double sucrose cushion with a top layer comprising 3 ml of 20% sucrose and a bottom layer comprising 3 ml of 50% sucrose (Beckman SW32 rotor; 160 000 g for 1.5h at 41C; Beckman Coulter, Fullerton, CA, USA). After ultracentrifugation, the medium and 1 ml of the upper sucrose cushion were removed and the next 4 ml, representing the recSFV particle-containing fraction, was collected and dialyzed in phosphatebuffered saline (PBS) overnight at 4 1C, dialysis membrane: CelluSep H1, 25 kDa cutoff (Orange Scientific, Braine-I'Alleud, Belgium). Next, the concentrated recSFV stocks were aliquoted and rapidly frozen. The concentration led to an approximate fivefold increase in the recombinant particle titer.
Real-time PCR recSFV virus quantification
To determine the genome copy number (that is, virus titer) of recSFV, viral RNA was isolated from the recSFV particle-containing aliquots (500 ml) using TRI Reagent BD (Sigma, St Louis, MO, USA) and dissolved in 30 ml of diethylpyrocarbonate-treated water. In all, 11 ml of RNA was reversetranscribed using the First-Strand cDNA Synthesis Kit (USB-Affymetrix, Santa Clara, CA, USA) applying the random hexamer oligonucleotide strategy. The following Luc gene-specific primers were generated using Beacon Designer 7 software (Premier Biosoft, Palo Alto, CA, USA): 5 0 -ACGGATTACCAGGGATTTC-3 0 (forward) and 5 0 -GCAGGCAGTTCTATGAGG-3 0 (reverse). The PCR produced a 183-bp DNA fragment using the MiniOpticon system (Bio-Rad). The reaction mixture contained the VeriQuest SYBR Green qPCR Master Mix (USB-Affymetrix), 600 nmol of each primer and 0. . Two hundred microliters of the 4T1 cell suspension were subcutaneously injected above the right shoulder blade of the mice. After 10 days, the tumor diameters were measured using linear callipers, and the tumor volume in mm 3 was calculated using the following formula: volume ¼ shorter measurement 2 Â longer measurement/2 (V ¼ (width) 2 Â length/2). 31 All obtained tumor volumes reached at least 1000 mm 3 . Tumor-free and 4T1 tumor-bearing mice (n ¼ 5 or more) were inoculated either i.v. or i.p. with 1 ml of recSFV particle-containing stocks. Two viral titers were used: 6 Â 10 9 per ml (concentrated and dialyzed as described above) and 2 Â 10 8 per ml (unconcentrated recSFV particle-containing medium). For in vivo application, recRNA was synthesized as described above. For i.v. and i.p. administration, 50 ml of the transcription mix containing 130 mg of recRNA was diluted in sterile diethylpyrocarbonate-treated water to a final volume of 250 ml with 5% glucose (w/v). The same amount of recRNA was applied for i.t. injection; however, the total volume (250 ml) was divided into five portions, and recRNA was injected into five different places in the tumor.
Analysis of Luc gene expression in mice organs
Luc gene expression analysis was performed by measuring the luciferase enzymatic activity in tissue homogenates at 24 (first day), 48 (second day) and 72 h (third day) or 7 days after recSFV virus administration and on the first and second day after recRNA administration. The organs were excised and manually homogenized in a 2 Â concentration of ice-cold lysis buffer (Cell Culture Lysis buffer, Promega) containing a protease inhibitor cocktail (10 ml per 1 ml of lysis buffer) (Sigma). The volume of lysis buffer used for each organ (or pairs of bilateral organs) is indicated in Table 1 . After homogenization, the samples were centrifuged for 10 min at 9000 g, and the protein concentration was determined in tissue lysates using the RC DC Protein Assay (DC Protein Assay, Bio-Rad). The luciferase activity was measured by adding 100 ml of freshly reconstituted luciferase assay buffer to 20 ml of the tissue homogenate (Luciferase Assay System, Promega). Luc gene expression was then quantified as relative light units (RLUs) using a conventional luminometer (Luminoskan Ascent, Thermo Scientific, Welwyn Garden City, UK). As a result of the different 4T1 tumor sizes and the high tissue density, tumors were weighed and homogenized in lysis buffer using a ratio of 200 ml of lysis buffer per 100 mg of tumor tissue (2:1).
To evaluate the vector distribution in the entire organism and to determine the viral dose per organ in general, rather than the viral dose per 1 mg of protein (RLU mg --1 ) as presented in other studies, 17, 32 the RLU values were expressed per total protein content in each organ (RLU per mg total). Nevertheless, using the data in Table 1 , where the total mg of proteins for each organ are indicated, the 'RLU per mg total' can be easily transformed into 'RLU mg --1 ' by dividing the RLU value presented in each diagram (see figures) by the total protein amount in the organs. RLUs were calculated as an average mean from the mice in a group (n ¼ 5 or more). As a negative control, mice were inoculated with PBS, and the maximal negative values in mice group n ¼ 7 (Table 1) were subtracted in the presented diagrams. Each experiment was repeated at least twice.
Statistical analysis
The RLU results are presented as the mean±s.e. The data were transformed to the logarithmic scale. Statistical analyses of the results were performed using Microsoft Excel and Statistica7 (StatSoft, Tulsa, OK, USA). Statistically significant differences were determined using Student's t-test (Po0.05).
RESULTS
Comparison of the recSFV virus biodistribution in tumor-free and 4T1 tumor-bearing mice
To investigate the biodistribution of recSFV in vivo, immunocompetent, tumor-free mice were i.v. or i.p. inoculated with 2 Â 10 8 v.p. recSFV/Enh.Luc (recSFV) particles. Luciferase expression analysis in the organ homogenates was performed on the first (24 h), second (48 h) or seventh day after virus inoculation ( Figures 1a and b) . The results are presented as the amount of RLUs per total protein (mg) in each organ homogenate, allowing for the evaluation of the recombinant virus distribution and Luc expression level in organs in general (see Materials and methods section).
On the first day, i.v. recombinant virus injection resulted in the highest level of transgene expression in the heart, moderate expression in the brain and lung, and low expression in the liver, kidney and ovary (Figure 1a ). On the second day, a rapid drop in the Luc expression was observed in all of the examined organs, with a further decrease on the seventh day, confirming the transient expression of luciferase by recSFV in vivo. In contrast to the results obtained after i.v. injection of the virus, i.p. administration revealed high levels of transgene expression on the first and second days (Figure 1b) . Nevertheless, starting from the third day, we observed a significant (Po0.05) decrease in the expression of the transgene in all organs (data not shown). Comparing the level of the Luc gene expression in all organs on i.v. and i.p. administration, the i.v. method provided a considerably higher level of Luc expression in the heart and lungs (that is, active blood circulation), whereas i.p. administration provided higher expression in the ovary, liver and kidney (more accessible organs by i.p. injection), and the Luc expression level in the brain was similar for both types of injections. In addition, the overall remaining level of Luc expression on the seventh day was noticeably higher after i.p. virus administration compared with i.v. injection (Figures 1a and b) , demonstrating the prolonged expression in the case of i.p. administration.
To evaluate the recSFV distribution in 4T1 tumor-bearing mice, animals were i.v. and i.p. inoculated using the same 2 Â 10 8 amount of recSFV v.p., and Luc gene expression was analyzed in organ and tumor homogenates on the first day after injection. Surprisingly, the most predominant tumor targeting (the highest RLU value in tumor) was detected after i.v. and i.p. recSFV In mice group, the negative values varied from zero to indicated maximal value. The organs of Balb/c mice were manually homogenized in 2 Â lysis buffer. The insoluble fraction was separated by centrifugation, and the protein concentration was measured using the RC DC Protein Assay (Bio-Rad, Hercules, CA, USA). The minimal and maximal values for the tumors are indicated. The background of luciferase detection system was measured in tissue homogenates on the first day after mice inoculation with PBS (mock). The maximal RLU values per mg total in mice group (n ¼ 7) are indicated.
administration (Figures 1c and d ), which provided a high level of transgene expression in tumors compared with the heart and lungs. As the absolute RLU values in the organs of tumor-bearing mice were significantly lower than the values observed in tumorfree mice (resembling some organs 7-day after inoculation), we did not analyze the subsequent days (that is, days second, third and seventh) after 2 Â 10 8 recSFV particles inoculation. Therefore, to evaluate the recSFV distribution in 4T1 tumor-bearing mice, the viral load was increased, and the results of i.v. and i.p. inoculations were investigated on the first, second and seventh days.
As shown in Figures 1e and f, no preferential Luc gene tumor expression was observed at high doses of recSFV (that is, 6 Â 10 9 v.p.), which were applied via i.v. and i.p. injection, as all organs received a high dose of the virus. Interestingly, we did not detect a strong decrease in Luc expression on the second day after i.v. administration (Figure 1e) , as was shown in the tumor-free animals with the low virus dose, and the expression indexes in all organs widely fluctuated. The ovary and liver can be efficiently targeted by i.p. administration (Figure 1f) . Remarkably, the transgene expression level in subcutaneous 4T1 tumors was not affected by the method of virus administration, demonstrating a similar Luc expression on i.v. and i.p. injections. However, i.p. administration provided a higher level of the Luc expression on the seventh day after inoculation in almost all organs and tumors. These data confirm that i.p. inoculation is able to provide prolonged transgene expression in tumor-free and tumor-bearing mice. Finally, despite the high virus dose, the overall expression level in tumor-bearing mice was significantly lower than that observed in tumor-free animals using a lower virus dose, whereas in tumorfree mice the same high virus dose provided the expected increase in Luc expression in all organs (data not shown).
Comparison of recRNA biodistribution in tumor-free and 4T1 tumor-bearing mice In addition to recombinant virus particle (recSFV) application, the unpacked self-replicating SFV RNA may be considered an The luciferase production in mouse organs after systemic recRNA administration is shown in Figures 2a and b . Surprisingly, in contrast to the virus distribution, where the maximal expression was detected in the heart, the highest recRNA expression was observed in the brain as a consequence of both i.v. and i.p. recRNA administrations. Other organs demonstrated a much lower transgene expression level compared with that of virus inoculation. Moreover, the injection type significantly influences the level of recRNA activity: only i.v. inoculation provides a relatively high level of Luc gene expression.
The recRNA distribution in 4T1 tumor-bearing mice was investigated only for i.v. inoculation (Figure 2c) , as the i.p. route did not demonstrate a high expression level. The results showed the highest recRNA expression in the brain, as was also detected in tumor-free animals. We observed low Luc gene expression in other examined organs and tumors on i.v. injection. Moreover, a rapid decrease in transgene expression in all examined organs, excluding the tumors, was observed on the second day after recRNA inoculation. Interestingly, the Luc gene expression in tumor-bearing mice was significantly lower compared with the tumor-free animals, and the same was observed for the recombinant virus vector expression.
In addition, the recRNA expression after i.t. administration was examined (Figure 2d ). For this purpose, i.t. injections consisting of 130 mg of recRNA were performed each day for 2 days, and Luc gene expression was analyzed in tumor and organ homogenates 1 day after the second injection (first day). Our results showed extremely high Luc gene expression in 4T1 tumors (Figure 2d ). Low vector activity in other organs showed poor RNA distribution in mice on i.t. administration. However, obvious transgene expression was found in the brain even after i.t. RNA vector inoculation.
recSFV virus and recRNA reinjection in Balb/c mice The transient mode of SFV-driven gene expression in vivo is demonstrated by the strong transgene expression decrease on the third day after inoculation. Virus readministration usually does not provide a significant enhancement or prolongation of transgene expression in mice. 17, 33 It is possible that the viral vector provoking the immune response is the reason for readministration failure. To develop an optimal strategy to increase and prolong transgene expression, several vector reinjection schemes using recSFV virus and recRNA combinations and different injection methods were evaluated (Figures 3a and b) .
Initially, (Figure 3a) , Balb/c mice were i.v. inoculated with 2 Â 10 8 recSFV virus, and 7 days later, one group (n ¼ 5) was i.p. readministered with the same amount of recSFV virus, the second group (n ¼ 5) was i.v. readministered with 130 mg of recRNA. Luciferase expression analysis was performed in tissue homogenates 24 h after recSFV virus or recRNA reinjection. To observe the increase in the transgene expression level, the results were compared with the values of the remaining Luc expression on the seventh day after the first recSFV virus inoculation. In both reinjection combinations (that is, recSFV virus and recRNA), we succeeded in significantly increasing the Luc expression in all (Figures 1b and 2a) . Nevertheless, the recRNA i.v. readministration values were comparable with the recSFV virus i.p. reinjection results, demonstrating the high potential of recRNA application, particularly if the brain is the targeted organ. According to another combination, the effect of recSFV virus/ recRNA reinjections using the i.p. method was investigated (Figure 3b ). For this purpose, Balb/c mice were i.p. inoculated with 2 Â 10 8 recSFV virus, and 7 days later, one group (n ¼ 5) received a readministration of the same amount of recSFV virus i.p., and the second group (n ¼ 5) received a readministration of 130 mg of recRNA i.p. Luciferase expression was measured in the organ homogenates that were collected on the first day (24 h) after reinoculation. Compared with the values on the seventh day, the repeated i.p. recSFV virus injection ensured a significant increase in the transgene expression only in the liver. In contrast with the i.v. recSFV virus readministration (Figure 3a) , the repeated i.p. method is much less effective for increasing the transgene expression at least with 7-day time interval. The recRNA i.p. reinjection also did not provide a remarkable increase in the transgene expression. As shown in Figures 1a and b (seventh day) , i.p. virus inoculation, in contrast to i.v. inoculation, provided prolonged Luc gene expression in all organs. Therefore, the relatively high values remaining on the seventh day after i.p. inoculation were not significantly increased by the recSFV virus and recRNA reinjections.
recSFV virus and recRNA reinjection in 4T1 tumor-bearing mice As the recRNA i.v. reinoculation in tumor-free mice demonstrated the significant increase in transgene expression that resembled recSFV reinoculation (Figure 3a) , we were interested in evaluating the recRNA readministration properties and transgene expression biodistribution in tumor-bearing mice that were primary i.v. injected with a high (6 Â 10 9 ) virus dose. For this purpose, 4T1 tumor-bearing mice were i.v. inoculated with 6 Â 10 9 recSFV virus, and after 7 days, the mice were i.v. inoculated with 130 mg of recRNA (Figure 4a ). Luc gene expression was measured in tissue homogenates 24 h after recRNA inoculation and compared with the Luc values on the seventh day after the first recSFV virus inoculation (that is, the remaining values). Using i.v. recRNA readministration, a significant increase in transgene expression was observed in the brain and heart. All other organs and tumors demonstrated statistically insignificant Luc expression differences.
Moreover, to investigate the ability of recRNA to prolong Luc gene expression, we evaluated repeated i.v. recRNA administration (Figure 4b ). For this purpose, 4T1 tumor-bearing mice were i.v. inoculated with 130 mg of recRNA and 7 days later the second 130 mg recRNA dose was i.v. reinjected. In addition, another group of mice was used to examine the prolongation of transgene expression by daily i.v. injections with 130 mg recRNA for 7 days (Figure 4b ). Luc expression was measured in tissue homogenates 24 h after the last recRNA injection.
The recRNA reinjection with 7-day interval provided the same level (that is, statistically insignificant differences) of Luc expression in all organs and tumors as was observed on the second day after the first recRNA inoculation. This observation indicates that recRNA is able to prolong transgene expression on systemic reinjection during a 7-day interval, since without reinjection the luciferase level dropped to the background (not shown). Remarkably, the daily reinjection of 130 mg recRNA did not enhance the transgene expression, demonstrating generally the same result as reinjection using 7-day interval (Figure 4b) .
Despite the fact that recRNA administration did not show high values of transgene expression, repeated i.v. recRNA injection resulted in the same level of expression in tumors (or even higher) as was detected after the first (primary) recRNA inoculation. Therefore, repeated recRNA injection could provide prolonged expression in contrast with repeated administration of recSFV, which does not result in the same level of transgene expression as was achieved after the first (primary) virus inoculation.
DISCUSSION
Biodistribution studies are important for the validation of viral vector tumor uptake and the assessment of their potential toxicity to normal tissues. In this study, we were interested in comparing the recSFV vector biodistribution in tumor-free and 4T1 tumorbearing mice after i.v. and i.p. administration of recombinant viral particles. Our results confirmed the broad in vivo recSFV dissemination that has been described by other authors, 17, 23 showing the highest SFV-driven transgene expression in organs with active blood circulation, including the heart and lung. Nevertheless, the virus dose may affect the vector distribution, toxicity and therapeutic effect. 34 In this study, we observed a significant correlation between recSFV dose and biodistribution in a 4T1 tumor model: the lower virus dose provided predominant tumor recSFV targeting as a consequence of both types (that is, i.v. and i.p.) of recombinant virus administration (Figures 1c and d) . Moreover, the increase in the recSFV dose changed not only the biodistribution pattern of the vector (the main expression switches to the heart), but also led to a decrease in transgene expression in tumors, whereas other organs demonstrated a high level of expression. Therefore, we conclude that the increase in recSFV titer does not provide predominant virus tumor targeting and enhancement of the i.t. transgene expression level in the 4T1 tumor model. In contrast, the abundant virus circulation more efficiently promotes the infection of the organs but not the tumors. A possible explanation for this difference could be the hypothesis that after virus injection, the majority of the virus particles circulating in blood infect cancer cells, which are more accessible for infection, and the rest of the virus disseminates to other organs, primarily leading to infection in the heart (and other organs depending on the method of administration).
The serum is known to inhibit alphavirus infectivity in vitro. One of the reasons is that components in serum (complement, immunoglobulins, and so on) interfere with the virus adsorption. In our experiments, the low recSFV dose represents the virus preparation containing cell culture medium with 1% FBS, in contrast to the high dose recSFV, which was purified by sucrose gradient and dialyzed in PBS. These two virus preparations (low dose and high dose) did not demonstrate the significant differences in recSFV distribution in tumor-free mice (not shown), only the level of Luc expression was higher using high virus dose, as was expected. We assume that the infectivity also is not affected significantly by FBS presence (10 ml per 1 ml dose) in low virus dose preparation, because the native mouse serum components already present in blood and equally interfere with the virus infection. Nevertheless, we do not exclude the influence of FBS and other factors of cell culture medium on immunity and transgene expression properties that have to be evaluated in longer period of time after recSFV inoculation (47 days).
In all experiments, we verified the higher transgene expression level in tumor-free animals as compared with 4T1 tumor-bearing mice. This was observed for the i.v. and i.p. methods and for the recSFV and recRNA inoculation experiments. The low level of viral expression in tumor-bearing mice may be affected by the upregulation of tumor stress factors and immune-related genes that suppress the virus entry and replication. We may also assume that vector uptake by tumor nodules in tumor-bearing mice leads to a decrease in the viral dose that is available for other organs, therefore reducing the total transgene expression level in tumorbearing mice.
The virus injection method (i.v. and i.p.) may significantly contribute to the virus allocation and affect the duration of transgene expression in an organism. Although recSFV did not demonstrate the most predominant tumor targeting at high doses, the ability of the vector to disseminate throughout the body may be important for gene delivery to a specific organ where metastases may be expected. With regard to our results, the liver, ovary and kidney were more efficiently targeted by i.p. recSFV administration, whereas the i.v. method targeted the other organs.
Moreover, in contrast to i.v. administration, i.p. recSFV inoculation revealed a higher Luc gene expression level on the seventh day, ensuring prolonged transgene synthesis. To solve the problem of transgene expression prolongation, other authors have attempted repeated vector administration. 33, 35, 36 It is likely that the repeated virus inoculation is suppressed by induction of antivector immune response. To avoid this, the recSFV particles were incapsulated into cationic liposomes. 36 Possibly, the liposome protects the incapsulated SFV particle from inactivation by immune system.
On the other hand, a naked recRNA vector could be used as an alternative strategy for repeated transgene delivery. In this study, we investigated the recRNA biodistribution on i.p., i.v. and i.t. administration. The use of naked RNA represents a safe, promising transgene delivery option, 37 but suffers from poor stability and lack of efficient and clinically feasible delivery technologies. In contrast, alphavirus replicon RNA probably has an increased stability because of its secondary structure, which may protect it from degradation. 38 In addition to high expression levels of inserted gene provided by self-replicating RNA, the various RNAspecies produced by the replicon amplification initiates antiviral program resulting in type I interferon production and induction of apoptosis. 6, 39 Therefore, the RNA-based vectors are potent immunostimulatory ligands providing excellent adjuvant properties and inducing strong cytopathic effect. As shown in previous studies, recRNA vectors have been used successfully for vaccine development through intramuscular injections. 26, 27, 40 Here, we demonstrated for the first time that i.t. administration of self-replicating recRNA provides efficient transgene expression in tumors without significant vector dissemination to organs (Figure 2d) , in contrast to recSFV particles i.t. inoculation. 32 Therefore, recRNA is a safe vector for i.t. application. As the i.t. recSFV administration was applied in numerous studies, we did not investigate this type of vector inoculation. However, the transgene expression efficiency of recSFV and recRNA vectors has to be compared in future.
Surprisingly, systemic recRNA inoculation revealed predominant transgene expression in brains of tumor-free and 4T1 tumorbearing mice (Figures 2a and c) . It is tempting to speculate that in contrast to the recSFV particles, recRNA molecules may cross the hematoencephalic barrier more efficiently. This recRNA property may potentially be used for brain-targeted gene delivery. However, the mechanisms of naked RNA delivery into target cells in vivo remain to be explored.
In this study, we showed that recRNA i.v. readministration can be successfully applied to prolong transgene expression without the risk of deterioration of viral vectors associated with the immune response. Nevertheless, for unknown reasons, neither recRNA reinjections nor recSFV particles reinjections allow for increasing the transgene expression up to values obtained after the primary vector inoculation (first day).
Here, we describe a comprehensive study of SFV vector distribution with regard to the vector injection type, viral dose, expression time and vector readministration. These results may be analyzed from a different point of view, depending on the priority of the vector application. In conclusion, we would like to emphasize the observed recSFV tropism in 4T1 tumors at certain doses of systemic viral inoculation. Thus far, only the Sindbis virus of the alphavirus genus has been considered to have tumortargeting properties; 41--44 however, a correlation with the virus dose has not been investigated in that case. Another important observation indicates a high potential for the self-replicating recRNA application for gene delivery demonstrated in this paper. The main advantages of recRNA vectors over the recSFV particles application include safety, reinoculation efficiency, reduced injection volume and simple preparation (that is, in vitro RNA synthesis over virus production). Our findings make SFV vectors attractive for future studies with respect to tumor targeting and gene delivery into organs that may be applied in combination with the recSFV virus and recRNA administration.
